
In a move that could fundamentally reshape the treatment landscape for Type 1 Diabetes (T1D) in the United States, Breakthrough T1D (formerly JDRF) has formally submitted a comprehensive response to the U.S. Department of Health and Human Services (HHS). The submission urges the federal government to reclassify deceased donor islets (DDIs) as "organs" rather than "biological drugs." This regulatory pivot aims to dismantle significant barriers that have, for decades, restricted life-saving islet transplantation to a handful of specialized centers, leaving thousands of patients without access to a proven cure for severe hypoglycemia.
n
Main Facts: The Struggle Between Biological Reality and Regulatory Frameworks
n
At the heart of this advocacy effort is a fundamental disagreement over how the human body’s components are categorized by the law. Currently, the U.S. Food and Drug Administration (FDA) regulates deceased donor islets—clusters of insulin-producing cells harvested from a donor pancreas—as "biological drugs" or "biologics." This classification requires hospitals and academic medical centers to meet the same stringent manufacturing standards as pharmaceutical companies producing synthetic medications.
n
For the T1D community, this classification is more than a semantic nuance; it is a clinical bottleneck. Because DDIs are treated as drugs, the process of isolating and transplanting them is subject to the Biologics License Application (BLA) process. This process is prohibitively expensive and logistically complex for most transplant centers, effectively preventing islet transplantation from becoming a standard-of-care procedure in the United States.
n
Breakthrough T1D, alongside a coalition of scientific leaders and advocacy groups, argues that unmodified DDIs are human tissue, not manufactured drugs. By reclassifying them as organs under the National Organ Transplant Act (NOTA), the oversight would shift to the Health Resources and Services Administration (HRSA) and the Organ Procurement and Transplantation Network (OPTN). This would align islet transplantation with the regulatory pathways used for kidneys, livers, and hearts, facilitating broader insurance coverage and standardized surgical protocols.
n
Chronology: The Road to the 2026 Request for Information (RFI)
n
The journey toward this regulatory crossroads has been years in the making, driven by a grassroots push from the T1D community and scientific pioneers.
n
- n
- Early 2026: Responding to intensified calls from patients and medical experts, Breakthrough T1D identifies the reclassification of DDIs as a top legislative and regulatory priority.
- March 6, 2026: Breakthrough T1D representatives meet with HHS Secretary Xavier Becerra (noted as Secretary Kennedy in the source text context) to present a formal proposal. The proposal outlines the legal and scientific justification for defining unmodified DDIs as organs under NOTA.
- Spring 2026: In the months following the initial proposal, Breakthrough T1D engages in a "full-court press" strategy. This includes the development of legal white papers, meetings with leadership at the FDA and HRSA, and the mobilization of "congressional champions" who authored three separate letters of support to the HHS.
- Summer 2026: The federal government issues a Request for Information (RFI), a formal solicitation for public and expert input on whether the classification of DDIs should be changed. This move signaled that the government was finally willing to reconsider its long-standing position.
- November 2026: The public comment period for the RFI reaches a crescendo. Breakthrough T1D submits its final, formal response, backed by a coalition including the Diabetes Research Institute Foundation, the Cure Alliance, and the Islets for US Collaborative. Over 10,000 comments from the public are recorded, reflecting the high stakes for the T1D community.
n
n
n
n
n
n
Supporting Data: The Clinical Case for Reclassification
n
The argument for reclassification is not merely theoretical; it is backed by decades of rigorous clinical data demonstrating that islet transplantation is a highly effective, though underutilized, therapy. Breakthrough T1D’s submission leans heavily on the results of the National Institutes of Health (NIH)-sponsored Clinical Islet Transplantation (CIT) Consortium trials.
n
The Success of CIT-07 and CIT-08
n
The CIT-07 phase 3 trial focused on islet transplantation alone for patients with T1D and severe hypoglycemia. The results were landmark:
n
- n
- 87.5% of participants achieved an HbA1c (average blood sugar) of below 7.0% at the one-year mark.
- More importantly, these participants experienced zero episodes of severe hypoglycemia, a life-threatening condition where blood sugar drops so low that the individual requires external assistance.
- Long-term follow-up in the CIT-08 trial showed that freedom from severe hypoglycemia remained above 90% for up to eight years.
- 74% of recipients achieved insulin independence (meaning they no longer required daily injections) at some point during their follow-up period.
n
n
n
n
n
Global Benchmarks
n
The United States currently stands as an outlier in its treatment of DDIs. In countries such as Canada, Australia, and several European nations, islet transplantation has long been integrated into the national organ or tissue framework. The "Edmonton Protocol," developed in Alberta, Canada, in the late 1990s, proved that islet transplantation could be a sustainable clinical service when regulated as a transplant rather than a pharmaceutical product. Breakthrough T1D argues that the U.S. must align with these global standards to maintain its status as a leader in medical innovation.
n
Official Responses: Breakthrough T1D’s Formal Position
n
In its formal submission to the RFI, Breakthrough T1D provided a clear roadmap for how the government should proceed. The organization’s recommendation hinges on a distinction between "unmodified" and "modified" cells.
n
The "Unmodified" Distinction
n
Breakthrough T1D proposes that unmodified DDIs—islets that are isolated and purified from a deceased donor pancreas and transplanted without genetic or chemical alteration—should be classified as organs. This would place them under the jurisdiction of HRSA and the OPTN.
Conversely, the organization agrees that the FDA should retain jurisdiction over manufactured or modified cell therapies. This includes islets that have been:
- Genetically modified to evade the immune system.
- Encapsulated in protective devices.
- Protein-coated or expanded in a lab setting.
- Differentiated from stem cells.
Expert Endorsements
The submission was bolstered by the expertise of world-renowned transplant surgeons and researchers, including Dr. Piotr Witkowski, Dr. Camillo Ricordi, and Dr. Norma Kenyon. These experts have long argued that the current FDA "drug" designation creates an "unworkable" environment for academic medicine, where the goal is patient care rather than commercial profit.
The conclusion of the submission is blunt: "DDI transplantation is a scientifically and clinically validated therapy that remains largely inaccessible in the United States because of a classification that does not match the biology of DDI or global practice."
Implications: What Reclassification Would Change
If the HHS moves forward with reclassification, the impact on the T1D community would be transformative. The implications span from the operating room to the insurance office.
1. Increased Access and Scaling
Currently, only a few centers in the U.S. have the resources to maintain a BLA for islet transplantation. Reclassifying DDIs as organs would allow any qualified transplant center to offer the procedure, utilizing the existing infrastructure of the OPTN. This would decentralize care and allow patients to receive transplants closer to home.
2. Insurance Coverage and CMS Action
One of the most significant hurdles to islet transplantation is cost. Because it is regulated as an experimental drug therapy by many insurers, coverage is often denied. If DDIs are classified as organs, it triggers a different set of reimbursement protocols under the Centers for Medicare & Medicaid Services (CMS). This would likely lead to mandatory coverage for eligible patients, making the procedure financially viable for the first time for many.
3. Strengthening American Competitiveness
By streamlining the regulatory path for unmodified islets, the U.S. can refocus its research efforts on the next generation of cures. Breakthrough T1D argues that a clearer framework for unmodified islets would actually help the FDA focus its resources on truly "novel" and "modified" cell therapies, accelerating the path toward a universal cure that does not require immunosuppression.
4. A Model for Future Tissue Therapies
The decision on DDIs could set a precedent for other cellular therapies. As regenerative medicine advances, the line between "tissue transplant" and "biological drug" will continue to blur. A successful reclassification of islets could provide a blueprint for how the U.S. regulates other life-saving human tissue products in the 21st century.
What Comes Next?
The closing of the RFI comment period on November 9th marks the beginning of a quiet but critical phase. The government must now review the 10,000+ submissions. Breakthrough T1D has cautioned the community that while the RFI is a monumental step, it is not a guarantee of action.
"An RFI is an important step, it is not a final step," the organization stated. "We will follow up on this submission in the coming weeks and continue to engage across HHS to keep progress moving."
For the thousands of Americans living with "brittle" Type 1 Diabetes—those for whom every night brings the fear of a fatal hypoglycemic event—the hope is that the government will finally listen to the science and the stories. The reclassification of deceased donor islets represents more than a regulatory change; it represents a path to freedom from the most dangerous complications of a relentless disease.